Diabetes
Conditions
Interventions
Theabrownin group:TB dose was 1.5g/ time. The route of administration was oral. The dose was given once.
Sponsors
Shanghai Sixth People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria 1. Participate voluntarily and sign informed consent before the test; 2. Age 18-70 years old, male or female; 3. Body mass index in the range of 19.0~35.0kg/m2 (including the critical value), male weight is not less than 50kg, female weight is not less than 45kg; 4. Screening within two weeks before the test, vital signs assessment, physical examination, urine routine, blood routine, blood biochemistry, chest radiograph, virology examination, blood pregnancy (female), 12-lead electrocardiogram examination, the results showed no abnormalities or abnormalities had no clinical significance; 5. Or patients with abnormal glucose tolerance: 2h postprandial blood glucose > 7.8mmol/L and <11.1mmol/L; 6. Subjects (including male subjects) have no pregnancy plans from signing informed consent to 6 months after the end of the trial; 7. The subjects were able to communicate well with the investigators and understood and complied with the requirements of the study.
Exclusion criteria
Exclusion criteria: Exclusion criteria 1. Patients with drug or food allergies who were judged by the researchers to be unsuitable for inclusion; 2. Hepatitis B surface antigen, hepatitis C virus antibody, HIV antibody or syphilis antibody, novel coronavirus nucleic acid test has one or more abnormalities and the investigator determined that clinical significance; 3. Patients with medical history or existing diseases of the heart, liver, kidney, endocrine, digestive tract, blood system and respiratory system (especially hypertension, hyperlipidemia, chronic ?gastrointestinal dysfunction with obvious digestive and absorption disorders); 4. Physical examination, clinical laboratory examination [blood routine, urine routine, blood biochemistry, coagulation, viral serology, pregnancy test (female), etc.], vital signs, 12-lead electrocardiogram examination, chest radiograph, abdominal B-ultrasonography, results showing abnormalities that the investigator 5. Thyroid function abnormalities determined by the investigator to be clinically significant; 6. The subject (female) was lactating; 7. Positive pregnancy test results of female subjects during the screening period; 8. The investigator considers that there are any circumstances that may affect the subject's ability to provide informed consent or to follow the protocol, or that the subject's participation in the study may affect the outcome of the study or his or her own safety.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| blood glucose; | — |
Secondary
| Measure | Time frame |
|---|---|
| gut microbiota;Metabonomics; | — |
Countries
China
Contacts
Public ContactAihua Zhao
Shanghai Sixth People's Hospital
Outcome results
None listed